Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ionis Pharmaceuticals is a biotechnology business based in the US. Ionis Pharmaceuticals stocks (IONS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $38.79 – a decrease of 9.67% over the previous week. Ionis Pharmaceuticals employs 757 staff and has a trailing 12-month revenue of around $660.7 million.
|Latest market close||$29.88|
|52-week range||$25.04 - $64.37|
|50-day moving average||$31.05|
|200-day moving average||$35.82|
|Wall St. target price||$49.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.37|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-01-14)||-9.67%|
|1 month (2021-12-23)||-8.65%|
|3 months (2021-10-22)||-1.84%|
|6 months (2021-07-23)||-21.43%|
|1 year (2021-01-22)||-51.61%|
|2 years (2020-01-23)||-50.53%|
|3 years (2019-01-23)||57.21|
|5 years (2017-01-23)||43.94|
Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $128.6 million.
The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$660.7 million|
|Gross profit TTM||$182.2 million|
|Return on assets TTM||-4.98%|
|Return on equity TTM||-57.65%|
|Market capitalisation||$4.7 billion|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 36.64
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 01/01/2019) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.18/100
Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 26.17/100
Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.29/100
Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $25.04 up to $64.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 0.9351. This would suggest that Ionis Pharmaceuticals's shares are less volatile than average (for this exchange).
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2. 5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.